Friends! In this video, I'm going to do an ELI LILLY stock analysis and discuss the risks and upside potential of LILLY stock
1 extracted signal · 1 resolved · 0 still active
The Patient Investor08 Aug 2025, 22:40 UTC
AI-generated source summary
The analysis discusses Eli Lilly's (LLY) recent performance and future prospects. LLY is currently trading at $640, down 14% after reporting earnings. The earnings report was strong, with EPS at $6.31 versus $5.57 expected and revenue at $15.56 billion versus $14.71 billion expected. Second-quarter revenue grew 38% year-on-year, and the company raised guidance on revenues and EPS. Sales for Mounjaro and Zepbound increased significantly, each by $2.1 billion. Sales grew 38% to $10.81 billion. The company is developing an oral GLP-1 pill for weight loss, which is going to be the major catalyst of LLY future growth, even though the trial results have been a little disappointing, with just 12% weight loss, while Wall Street was expecting around 15%. LLY is facing the risk of potential drug price controls from President Trumps. The analyst does not currently own LLY. Using analyst estimates for 37% growth in 2026, then decelerating growth to 15% by 2030. Using PE ratio of 25 and a 1% dividend, it shows 129% upside to $1434 per share, and it is required $717 per share to get a double on LLY.
AI-generated summary based on the source content.
Evidence and evaluation progress
- Original source published
The analyst published the original source item.
- Source recorded by Tahlil Plus
The public source was preserved as the evidence record for this case.
- Market predictions extracted
1 eligible signal linked to this case.
- Outcome tracking started
Tahlil Plus began monitoring the extracted predictions.
- First prediction resolved
The first evaluable outcome in this case reached a terminal result.
- Case evaluation completed
All evaluable predictions in this case reached terminal outcomes.
Signals in this source
More Prediction Case Files from The Patient Investor
Why I Don't Own Google Stock & When I'm Buying
The CHEAPEST Quality Stock In The Stock Market!
Intuitive Surgical Stock Analysis! Risks & Upside Potential
There Is NO AI BUBBLE! I’m Buying Every Dip
2 Stocks I'm Buying In The Next 2 Weeks
Netflix Stock Is FINALLY A Buy!
The Patient Investor
Tahlil Plus independently records and evaluates public market predictions. Extraction may be AI-assisted and results follow the Tahlil Plus methodology. This information is not financial advice.